Table 3. Maternal and gestational outcomes in women with human immunodeficiency virus (HIV) infection, according to the type of hospital admission funding. State of Rio de Janeiro, 2021-2023^!.

Indicators		Total (N=15) n (%: 95%CI)	Public funding (N=14) n (%: 95%CI)	Private funding (N=1) n (%: 95%CI)
Maternal outcomes in women with HIV infection
	Potentially life-threatening condition*	2 (7.8: 0.9–43.7)	2 (8.5: 1.0–47.1)	0
	Maternal near miss*	1 (2.2: 0.1–33.8)	1 (2.4: 0.1–37.3)	0
	Maternal death*	0	0	0
Pregnancy outcomes in women with HIV infection
	Early fetal loss	1 (4.2: 0.3–35.5)	1 (4.6: 0.4–37.9)	0
	Stillbirth	1 (4.5: 0.4–33.2)	1 (4.9: 0.5–35.2)	0
Pregnancy outcomes in live births of women with HIV infection		N=13 n (%: 95%CI)	N=12 n (%: 95%CI)	N=1 n (%: 95%CI)
Neonatal death		0	0	0
Low birth weight		2 (17.8: 1.8–72.2)	2 (19.6: 2.0–74.6)	0
Prematurity		1 (6.1: 0.4–48.8)	1 (6.7: 0.5–52.1)	0

IC95%: 95% confidence interval;

^*according to definitions by the World Health Organization; early fetal loss: fetal death with weight <500 g and gestational age <22 weeks; stillbirth: fetal death with weight ≥500 g or gestational age ≥22 weeks; neonatal death: death occurring up to the 27^th day of life; low birth weight: live birth with birth weight <2,500 g; prematurity: live birth with gestational age <37 weeks;

^!due to data weighting, frequencies are generated with decimals and were rounded to avoid presenting them as fractions of cases. Therefore, the percentages presented in parentheses may be slightly different from those calculated based on the numbers presented (numerator and denominator), especially for variables and categories with low frequency.